This from a company 21 April, 2022 ASX release - obviously this is the final data presentation.
What is new in the data abstract, is this (from Dr Wen and Dr De Groot) -
---------------------------------------------------------------------------------------------------------
"At the MTD FDG-PET data provide evidence that paxalisib has the ability to exert biological effect in tumour tissue, irrespective of fed or fasted status "
----------------------------------------------------------------------------------------------------------
2104/2022
Patrick Wen, MD, Principal Investigator at Dana-Farber Cancer Institute, commented, “we look forward to presenting the final data from this phase II study and continuing our investigations in the multi-drug GBM AGILE study. Glioblastoma is a devastating diagnosis and we are encouraged by the prospect of providing new hope to this patient community”
- Forums
- ASX - By Stock
- GBM PAXALISIB ESMO 09/09/2022
This from a company 21 April, 2022 ASX release - obviously this...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online